KR20180117693A - 포스파티딜이노시톨 3-키나제 감마의 신규 억제제 - Google Patents

포스파티딜이노시톨 3-키나제 감마의 신규 억제제 Download PDF

Info

Publication number
KR20180117693A
KR20180117693A KR1020187028625A KR20187028625A KR20180117693A KR 20180117693 A KR20180117693 A KR 20180117693A KR 1020187028625 A KR1020187028625 A KR 1020187028625A KR 20187028625 A KR20187028625 A KR 20187028625A KR 20180117693 A KR20180117693 A KR 20180117693A
Authority
KR
South Korea
Prior art keywords
dihydro
oxo
methyl
cyclopropyl
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187028625A
Other languages
English (en)
Korean (ko)
Inventor
미카엘 모게마르크
닐스 펨베르톤
옌스 피터슨
매튜 페리
콘스탄티노스 카라벨라스
파볼 슬라토이쉬
로나 콕스
크리스티안 튀르샨
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20180117693A publication Critical patent/KR20180117693A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187028625A 2016-03-10 2017-03-09 포스파티딜이노시톨 3-키나제 감마의 신규 억제제 Abandoned KR20180117693A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306328P 2016-03-10 2016-03-10
US62/306,328 2016-03-10
PCT/EP2017/055552 WO2017153527A1 (en) 2016-03-10 2017-03-09 Novel inhibitors of phosphatidylinositol 3-kinase gamma

Publications (1)

Publication Number Publication Date
KR20180117693A true KR20180117693A (ko) 2018-10-29

Family

ID=58264542

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028625A Abandoned KR20180117693A (ko) 2016-03-10 2017-03-09 포스파티딜이노시톨 3-키나제 감마의 신규 억제제

Country Status (13)

Country Link
US (2) US10858355B2 (enExample)
EP (1) EP3426652B1 (enExample)
JP (1) JP6893520B2 (enExample)
KR (1) KR20180117693A (enExample)
CN (1) CN108779110B (enExample)
AR (1) AR107840A1 (enExample)
AU (1) AU2017229445B2 (enExample)
BR (1) BR112018068075A2 (enExample)
CA (1) CA3015893C (enExample)
EA (1) EA036388B1 (enExample)
MX (1) MX387125B (enExample)
TW (1) TWI746525B (enExample)
WO (1) WO2017153527A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) * 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020210379A1 (en) 2019-04-10 2020-10-15 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors
AU2020288610A1 (en) 2019-06-04 2022-01-27 Arcus Biosciences, Inc. 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
CN115611883B (zh) * 2021-07-13 2025-03-28 生物岛实验室 一种双环结构的PI3Kα抑制剂及其制备方法和用途
CN119768404A (zh) * 2022-09-01 2025-04-04 上海海雁医药科技有限公司 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
EP4585596A4 (en) * 2022-09-09 2025-12-10 Shanghai Yingli Pharm Co Ltd Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
EP4734987A1 (en) 2023-06-30 2026-05-06 Forschungsverbund Berlin E.V. Thiazolo tetrahydrochinoline compounds as class ii phosphoinositide 3-kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
AU2007207743B2 (en) * 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
JP2009535386A (ja) * 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
CA2752596A1 (en) * 2009-02-17 2010-08-26 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
RU2573569C2 (ru) * 2009-12-22 2016-01-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
CN104379573A (zh) * 2012-04-20 2015-02-25 艾伯维公司 异吲哚酮衍生物
RU2675814C2 (ru) 2013-09-25 2018-12-25 Вертекс Фармасьютикалз Инкорпорейтед 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
EA201891931A1 (ru) 2019-04-30
EA036388B1 (ru) 2020-11-03
TW201808945A (zh) 2018-03-16
WO2017153527A1 (en) 2017-09-14
US10858355B2 (en) 2020-12-08
AU2017229445B2 (en) 2019-07-11
US20210047312A1 (en) 2021-02-18
BR112018068075A2 (pt) 2019-01-08
JP6893520B2 (ja) 2021-06-23
JP2019507788A (ja) 2019-03-22
AR107840A1 (es) 2018-06-13
MX2018010894A (es) 2018-11-09
MX387125B (es) 2025-03-18
US20200299289A1 (en) 2020-09-24
EP3426652A1 (en) 2019-01-16
CA3015893C (en) 2021-11-09
CN108779110A (zh) 2018-11-09
CA3015893A1 (en) 2017-09-14
AU2017229445A1 (en) 2018-10-25
CN108779110B (zh) 2021-10-29
TWI746525B (zh) 2021-11-21
EP3426652B1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP6893520B2 (ja) ホスファチジルイノシトール３−キナーゼガンマの新規の阻害剤
JP6535022B2 (ja) ヘテロアリールｓｙｋ阻害剤
CA2870087C (en) Substituted isoquinolin-1(2h)-one compounds and their use as phosphoinositide 3-kinase (pi3k) inhibitors
KR102226098B1 (ko) 5-[2-(피리딘-2-일아미노)-1,3-티아졸-5-일]-2,3-디하이드로-1h-이소인돌-1-온 유도체 및 포스파티딜이노시톨 3-키나제 델타 및 감마의 이중 억제제로서의 이의 용도
KR20160098392A (ko) Nrf2 조절제
KR20130049766A (ko) 트리사이클릭 피라졸 아민 유도체
KR20050044476A (ko) 페닐 치환된 트리아졸 및 ａｌｋ5 키나제의 선택적억제제로서의 그의 용도
WO2025034951A1 (en) Pharmaceutical compounds and compositions as c-kit kinase inhibitors
CN102816128B (zh) 含杂环基的氨基甲醇衍生物及其盐类及合成方法和用途
HK1257837A1 (en) Novel inhibitors of phosphatidylinositol 3-kinase gamma
TW202328123A (zh) 含有嘧啶之含氮雙環化合物
WO2022070289A1 (ja) ピリミジン含有含窒素二環化合物
HK1204787A1 (en) Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904